Trial Profile
A Prospective, Open label, Single-arm Clinical Trail to Evaluate the Safety and Efficacy of Apatinib MesylateTablets in Advanced Epithelial Ovarian Cancer failing to respond to Second-line Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 24 Nov 2016 Planned patient number changed from 20 to 40 since Chinese CTR is the only source.
- 27 Apr 2016 New trial record